Search

Search Constraints

You searched for: Author/Creator Priou, Frank

Search Results

1. A Phase II Trial Evaluating the Efficacy and Safety of Efavirenz in Metastatic Castration-Resistant Prostate Cancer. (29th October 2014)

2. A Phase II Trial Evaluating the Efficacy and Safety of Efavirenz in Metastatic Castration‐Resistant Prostate Cancer. (29th October 2014)

3. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Issue 10336 (30th April 2022)

4. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Issue 7 (July 2015)

5. Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects. (December 2021)

6. Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database. (January 2020)

7. Corrigendum to "Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database" [Eur J Canc 125, (January 2020) 153–163]. (September 2020)

8. Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study. (March 2023)

9. Erratum to 'Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database' [European Journal of Cancer, Volume 125 (January 2020) Pages 153–163]. (September 2020)

10. MP27-13 LONG-TERM SAFETY OF DAROLUTAMIDE AMONG PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO RECEIVED MORE THAN 4 YEARS OF THERAPY. (May 2022)